ACCD
Accolade, Inc. Common StockACCD
ACCD
Delisted
ACCD was delisted on the 7th of April, 2025.
About: Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
Employees: 2,400
Financial journalist opinion
Neutral
GlobeNewsWire
18 hours ago
Wellspring Launches Next-Gen Innovation Platform, Accolade Core
Accolade Core and the Core Six Framework Give Innovation Leaders the Tools to Deliver Measurable Business Growth Accolade Core and the Core Six Framework Give Innovation Leaders the Tools to Deliver Measurable Business Growth
Neutral
Reuters
1 week ago
Pernod completes sale of wine portfolio to Accolade Wines owner
Pernod Ricard has completed the sale of its international wine portfolio, including brands like Jacob's Creek, to Accolade Wines owner Australian Wine Holdco, it said on Wednesday.
Neutral
CNBC
1 month ago
Digital health startup Transcarent takes Accolade private in $621 million deal
Transcarent on Tuesday announced it has completed its $621 million acquisition of Accolade. Accolade shareholders received $7.03 per share in cash, and the company will no longer be listed on the Nasdaq.
Neutral
Business Wire
1 month ago
Transcarent Completes Merger With Accolade
SAN FRANCISCO & SEATTLE--(BUSINESS WIRE)-- #HealthWayFinding--Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. With the completion of the transaction, Transcarent will offer a health and care experience that is unmatched in its abil.
Neutral
GlobeNewsWire
1 month ago
Accolade Stockholders Approve Merger Between Accolade and Transcarent
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission.
Neutral
PRNewsWire
2 months ago
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem
Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE , March 6, 2025 /PRNewswire/ -- Accolade, Inc. (Nasdaq: ACCD) has partnered with Oshi Health , a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.
Positive
Zacks Investment Research
2 months ago
Has Accolade (ACCD) Outpaced Other Business Services Stocks This Year?
Here is how Accolade (ACCD) and Casella (CWST) have performed compared to their sector so far this year.
Neutral
Business Wire
2 months ago
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (NASDAQ: ACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders. Halper Sadeh encourages Accolade shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Accolade and its board.
Neutral
GlobeNewsWire
2 months ago
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies.
Neutral
PRNewsWire
3 months ago
Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering
Effort broadens healthcare access and removes barriers to primary care and weight management services SEATTLE , Feb. 4, 2025 /PRNewswire/ -- Today, Accolade, Inc. (NASDAQ: ACCD) announced that its direct-to-consumer virtual healthcare offering, PlushCare, is now accepting Medicare Part B, expanding care access to 64 million beneficiaries across all 50 states. PlushCare offers quality primary care, clinical weight management services, and mental health support from leading providers.
Charts implemented using Lightweight Charts™